IKT

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Inhibikase Therapeutics Inc

NASDAQ | IKT

1.52

USD

$0.00

(

0.00%

)

At Close (As of Nov 28, 2025)

$119.23M

Market Cap

-

P/E Ratio

-0.04

EPS

$4.20

52 Week High

$1.33

52 Week Low

HEALTHCARE

Sector

IKT Chart

Recent Chart
Price Action

IKT Technicals

Tags:

IKT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$26K
Total Revenue $0
Cost Of Revenue $26K
Costof Goods And Services Sold $26K
Operating Income -$29M
Selling General And Administrative $11M
Research And Development $17M
Operating Expenses $29M
Investment Income Net -
Net Interest Income $1.1M
Interest Income $1.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $26K
Income Before Tax -$28M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$28M

Revenue & Profitability

Earnings Performance

IKT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $99M
Total Current Assets $98M
Cash And Cash Equivalents At Carrying Value $56M
Cash And Short Term Investments $56M
Inventory -
Current Net Receivables -
Total Non Current Assets $149K
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $41M
Other Current Assets $908K
Other Non Current Assets -
Total Liabilities $3.7M
Total Current Liabilities $3.7M
Current Accounts Payable $943K
Deferred Revenue -
Current Debt -
Short Term Debt $111K
Total Non Current Liabilities $0
Capital Lease Obligations $111K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $111K
Other Current Liabilities $2.7M
Other Non Current Liabilities -
Total Shareholder Equity $95M
Treasury Stock -
Retained Earnings -$94M
Common Stock $69K
Common Stock Shares Outstanding $69M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$19M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $26K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$37M
Cashflow From Financing $103M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$28M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$26K
Total Revenue $0
Cost Of Revenue $26K
Costof Goods And Services Sold $26K
Operating Income -$29M
Selling General And Administrative $11M
Research And Development $17M
Operating Expenses $29M
Investment Income Net -
Net Interest Income $1.1M
Interest Income $1.1M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $26K
Income Before Tax -$28M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$28M
Comprehensive Income Net Of Tax -
Ebit -$28M
Ebitda -$27M
Net Income -$28M

IKT News

IKT Profile

Inhibikase Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Inhibikase Therapeutics, Inc. is an Atlanta-based clinical-stage biopharmaceutical company focused on developing innovative therapies for Parkinson's disease and related neurodegenerative disorders. Utilizing a unique dual-targeting strategy, the company aims to address both central and peripheral neurodegeneration mechanisms, targeting critical unmet needs within the Parkinson's disease patient community. With a promising pipeline of clinical candidates, Inhibikase is strategically positioned to make significant contributions to the treatment landscape, ultimately enhancing the quality of life for individuals affected by these debilitating conditions.

LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
LPTX
+368.57%
$2.05
KTTA
+38.67%
$1.47
NVDA
-1.80%
$177.00
HBI
-1.82%
$6.47
AMZE
+21.21%
$0.48
VINE
+21.21%
$0.48
TLRY
-21.06%
$0.81
INTC
+10.18%
$40.56
BITF
+12.25%
$3.48
IPG
-1.95%
$24.57
TWOH
-15.38%
$0.00
BYND
-3.74%
$0.98
YGMZ
-9.59%
$0.11
AXDX
-61.36%
$0.03
RUBI
-26.17%
$0.15
BMNR
+4.34%
$33.12
CLSK
+12.26%
$15.10
ADAP
-15.14%
$0.05
ASST
-0.88%
$1.12
PLUG
+1.51%
$2.01
SOND
-23.45%
$0.12
SNAP
+0.91%
$7.68
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
INHD
-0.99%
$0.22
ADD
-25.47%
$0.05
CHR
-3.48%
$0.04
BIYA
+17.05%
$0.29
AAL
+0.86%
$14.05
TSLA
+0.84%
$430.17
SRM
+53.27%
$10.30
CIFR
+6.26%
$20.35
ONMD
+30.28%
$1.85
BMNU
+8.84%
$8.18
ONDS
-4.12%
$7.90
MARA
+6.30%
$11.81
WULF
+4.51%
$15.51
NIO
+0.73%
$5.50
F
+0.68%
$13.28
BURU
+9.84%
$0.24
GPUS
-9.24%
$0.30
WLGS
-5.57%
$0.04
MTSR
-0.35%
$70.50
SOFI
+4.31%
$29.72
VALE
+0.79%
$12.61
GOOGL
+0.07%
$320.18
BTBT
+2.58%
$2.38
DEFT
+9.35%
$1.52
ADTX
+21.01%
$3.80
BTG
+3.35%
$4.62
DVLT
-4.69%
$2.03
GRAB
+2.44%
$5.45
ACHR
+4.00%
$7.79
AFMD
-34.94%
$0.18
PFE
+0.11%
$25.74
CRCL
+10.03%
$79.93
SMX
+250.80%
$61.04
KWM
+13.63%
$0.75
DNN
0.00%
$2.56
IBRX
+10.79%
$2.36
VEEE
+45.50%
$2.59
RIOT
+7.82%
$16.13
AMZN
+1.77%
$233.22
CAN
+9.78%
$1.01
AAPL
+0.46%
$278.85
NWTN
-9.09%
$0.70
AIIO
-9.09%
$0.70
AG
+12.73%
$15.23
WBD
+0.50%
$24.00
APLD
+8.66%
$27.10
NGD
+6.50%
$8.35
GOOG
-0.05%
$320.12
IREN
-1.32%
$47.81
RIG
+2.55%
$4.41
GRYP
-10.38%
$1.38
BAC
+1.24%
$53.65
MODV
-25.22%
$0.43
AMD
+1.53%
$217.53
RIVN
+4.20%
$16.86
SMR
+5.04%
$20.00
TMC
+19.38%
$6.96
PLTR
+1.61%
$168.45
CDE
+6.67%
$17.27
ITUB
+1.82%
$7.80
AGNC
+0.47%
$10.49
CRCA
+19.56%
$4.40
T
+0.77%
$26.02
AMC
+6.52%
$2.45
VHAI
-25.00%
$0.00
NVO
+1.31%
$49.35
CRCG
+20.00%
$2.82
MSTR
+0.87%
$177.18
NFLX
+1.35%
$107.58
SAND
-6.04%
$12.12
BBD
+0.54%
$3.70
BTE
+1.89%
$3.22
MSFT
+1.34%
$492.01
HBAN
+0.18%
$16.30
HL
+5.32%
$16.82
CRWV
-1.57%
$73.12
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.